A-500359 A exhibited reversible inhibition, which was mixed type undecaprenyl-phosphate, respectively. A-500359 A, C, D and G showed antimicrobial activity against Mycobacterium smegmatis. As a single intravenous injection of A-500359 A at a dose of 500mg/kg showed no toxicity in mice, it was suggested that the capuramycin derivatives might become candidates as novel therapeutic agents for various diseases caused by Mycobacteria including tuberculosis.
In the preceding paper, we described the taxonomy of the producing strain, SANK 60196, and the fermentation, The method described by BRANDISH et al.5) was partially modified as follows. Assay constituents were added to each well in a 96-well microtitre polystyrene plate (Corning Coaster, #3694) in the following order. Fifty microliters of 200mM Tris-HCl buffer (pH 7.5) containing 100mM KCl and 50mM MgCl2 were added to each well followed by solution containing 2.5mg/ml phosphatidylglycerol, 3.65mg/ml undecaprenyl-phosphate and 10% (v/v) Triton X -100 were added to the assay mixture followed by addition of the test sample. The reaction was started by concomitant with the formation of lipid-linked product was monitored at 538nm (excitation at 355nm). As shown in Table  1 , these compounds inhibited incorporation of radio-labeled UDP-GlcNAc into cell wall respectively. The enzyme was pre-incubated for 10 minutes at room temperature in Tris-HCl buffer (pH 8.0) with or without A-500359 A and the remaining activity was determined 
